Format

Send to

Choose Destination
Int J Urol. 2017 May;24(5):342-351. doi: 10.1111/iju.13325. Epub 2017 Mar 21.

Current status of clinical trials assessing oncolytic virus therapy for urological cancers.

Author information

1
Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
2
Division of Innovative Cancer Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Abstract

Oncolytic virus therapy has recently been recognized as a promising new option for cancer treatment. Oncolytic viruses replicate selectively in cancer cells, thus killing them without harming normal cells. Notably, T-VEC (talimogene laherparepvec, formerly called OncoVEXGM-CSF ), an oncolytic herpes simplex virus type 1, was approved by the US Food and Drug Administration for the treatment of inoperable melanoma in October 2015, and was subsequently approved in Europe and Australia in 2016. The efficacies of many types of oncolytic viruses against urological cancers have been investigated in preclinical studies during the past decade, and some have already been tested in clinical trials. For example, a phase I trial of the third-generation oncolytic Herpes simplex virus type 1, G47Δ, in patients with prostate cancer was completed in 2016. We summarize the current status of clinical trials of oncolytic virus therapy in patients with the three major urological cancers: prostate, bladder and renal cell cancers. In addition to Herpes simplex virus type 1, adenoviruses, reoviruses, vaccinia virus, Sendai virus and Newcastle disease virus have also been used as parental viruses in these trials. We believe that oncolytic virus therapy is likely to become an important and major treatment option for urological cancers in the near future.

KEYWORDS:

G47Δ; Herpes simplex virus; clinical trial; oncolytic; virus therapy

PMID:
28326624
DOI:
10.1111/iju.13325
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center